Tim Mullaney writes mostly on economics, health care and technology. He was national economics correspondent at USA Today from 2011 to 2014 and earlier served as E-Business Editor of BusinessWeek. Follow him on Twitter at @timmullaney.
Famous value investors like Bill Miller are chasing growth stocks. It could be a sign we are approaching a bottom in an aging bull market.
Estimates of how much money Tesla will need in the next two years range from $2 billion to $10 billion, a swing factor that is so large because it depends on meeting car production targets.
Apple is the tech stock most likely to win the race against Alphabet and Amazon to a $1 trillion market cap, but not only because it's already the closest to that value. It's proving something new to the market.
As the US and Europe move to regulate Facebook amid privacy concerns, the social media giant's best bet may be continued growth in developing markets.
The most common knee surgery performed on seniors is for a meniscus tear. It's not only costly, it often doesn't work.
Gender affirmation surgery is becoming a reality for 1.4 million American trans people as work health insurance and Obamacare coverage bring down the cost of a sex change.
If Trump slaps $60 billion worth of tariffs on China today, it could retaliate against major U.S. exports, such as Boeing, a darling of the Dow.
Doctors at Johns Hopkins are proposing a new, earlier way to identify potential colon cancer patients that is less invasive and simpler than a colonoscopy.
If Trump slaps $60 billion worth of tariffs on China, it could retaliate against major U.S. exports, such as Boeing, a darling of the Dow.